Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Seamless Therapeutics

    • Home
    • Seamless Therapeutics
Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026

Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...

Recent updates

  • Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation
  • Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing
  • Merck Establishes Chongqing China Branch in Milestone Expansion
  • Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus
  • Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Company

Merck Establishes Chongqing China Branch in Milestone Expansion

Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.